Cash and cash equivalents and marketable securities as of March 31, 2024, were $566.5 million, compared with $187.7 million as of December 31, 2023.Based on cash, cash equivalents and marketable securities, as of March 31, 2024, and current operating plans, the Company expects its cash runway to be sufficient to fund operations through 2027.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CGON:
- CG Oncology Reports First Quarter 2024 Financial Results and Provides Business Updates
- 3 Best Stocks to Buy Now, 5/9/2024, According to Top Analysts
- 3 Best Stocks to Buy Now, 5/7/2024, According to Top Analysts
- Cantor Fitzgerald biotech analysts hold an analyst/industry conference call
- 3 Best Stocks to Buy Now, 5/6/2024, According to Top Analysts